1. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial. Issue 5 (May 2021) Authors: Risitano, Antonio M; Röth, Alexander; Soret, Juliette; Frieri, Camilla; de Fontbrune, Flore Sicre; Marano, Luana; Alashkar, Ferras; Benajiba, Lina; Marotta, Serena; Rozenberg, Izabela; Milojevic, Julie; End, Peter; Nidamarthy, Prasanna K; Junge, Guido; Peffault de Latour, Régis Journal: Lancet Issue: Volume 8:Issue 5(2021) Page Start: e344 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗